The unit located in Saint Remy sur Avre, France, operated by Delpharm, will make the Pfizer product (branded as Comirnaty), which could deliver approximately 51 million additional doses in 2021, after passing the committee's scrutiny of human medicines (CHMP) of the EMA. A new production line was also approved at the BioNTech plant in the German city of Marburg, which will allow it to increase the production capacity of active substances in the vaccine to around 410 million this year.

The CHMP is also considered suitable for the manufacture of vaccines by Spikevax, the trade name for the product of Moderna, the factory located in the city of Bloomington, in the US state of Indiana, operated by the multinational Catalent, which manages other control and packaging points for the vaccine. With the further expansion, announced in late July, of the production process of active substances at the two plants in the US, Massachusetts and New Hampshire, the CHMP decision will allow the production of 40 million additional doses of Moderna for the European market during the third quarter of 2021.

Authorization by the EMA in these cases does not require a decision by the European Commission, so these factories are now operational for the EU "immediately." The European Commissioner for Health, Stella Kyriakides, welcomed, on the social network Twitter, the work of the EU to "expand the production capacity" of vaccines, hoping that it "continues without stopping", and recalled that Brussels delivered six months ago “ sufficient vaccines to immunise 70 percent of adults" and that today's EMA decision will allow for "up to 500 million additional doses" in 2021.